BioCryst culls Factor D inhibitor; Elevation Oncology’s stock plummets

Plus, news about Tenax Therapeutics:

BioCryst discontinues Factor D inhibitor: This is after finding that “clinical activity observed was less than other therapies on the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Meta Title: “Forma Therapeutics Inc Files Patent for USP30 Inhibitor Compounds

Share this article According to GlobalData’s company profile on Forma Therapeutics, Cancer treatment biomarkers was a key innovation area identified from patents. Forma Therapeutics‘s grant

April 1, 2024

Biopharma Collaboration: Roadmap Towards the Facility of the Future

Panelists: Janmeet Anant, PhD, PMP, RACSenior Regulatory ConsultantMerck Guido Kremer-van der KampSenior Consultant,Global BioPharm Center of ExcellenceMerck Adam SokolnickiDirector of the MSAT-Downstream group of Biomanufacturing

June 15, 2023

Philips recalls MRI machines due to risk of explosion

Listen to the article 3 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief: Philips recalled certain magnetic resonance

December 22, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.